TherapeuticsMD has been granted a patent for progesterone formulations that allow for reduced dosage while maintaining efficacy. The pharmaceutical composition includes progesterone, a solubilizing agent, and a nonionic surfactant, offering potential benefits for patients in need. GlobalData’s report on TherapeuticsMD gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights TherapeuticsMD Inc

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on TherapeuticsMD, Telomerase reverse transcriptase screening was a key innovation area identified from patents. TherapeuticsMD's grant share as of January 2024 was 41%. Grant share is based on the ratio of number of grants to total number of patents.

Progesterone formulations with reduced dosage for oral administration

Source: United States Patent and Trademark Office (USPTO). Credit: TherapeuticsMD Inc

A recently granted patent (Publication Number: US11865179B2) discloses a pharmaceutical composition designed for the oral administration of progesterone to individuals in need of such treatment. The composition includes progesterone, a solubilizing agent predominantly consisting of C6-C12 fatty acid tri-esters of glycerol, and a nonionic surfactant, specifically lauroyl polyoxyl-32 glycerides. The progesterone content in the composition ranges from 20 to 50 weight percent, with options for specific dosages between 25 mg to 200 mg, such as 75 mg or 150 mg.

Furthermore, the patent details the inclusion of additional components like C6-C12 fatty acid mono-esters and di-esters of glycerol in the solubilizing agent, along with the option to incorporate an antioxidant like butylated hydroxy toluene. The composition, which can be encapsulated in a gelatin capsule, has a total mass of less than 500 mg and specific weight percentages for progesterone, solubilizing agent, and non-ionic surfactant. The formulation aims to provide an effective and convenient method for administering progesterone orally, catering to the varying needs and dosages required for different individuals in need of such treatment.

To know more about GlobalData’s detailed insights on TherapeuticsMD, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies